Scientists at Wuxi XDC (Shanghai) Co. Ltd. and Wuxi XDC Singapore Pvt Ltd. have divulged antibody-drug conjugates comprising antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
The natural product diterpene andrographolide, from Andrographis paniculata (‘creat’ or ‘green chiretta’), shows promising antitumor activity, so researchers from Nanjing Tech University and collaborators in mainland China and Hong Kong derivatized it by enlarging the six-membered decalin ring at position 3 to generate a seven-membered ring or by annulating the decalin at positions 3 and 19 through fusion with isoxazole.
MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis. Because their expression patterns differ across tumor types and stages, miRNA profiles hold strong potential as noninvasive diagnostic and prognostic biomarkers.
Revolution Medicines Inc. has developed and presented data for their KRAS codon 13-targeting compound, RMC-8839, for treating non-small-cell lung cancers.
Forx Therapeutics AG presented data on their PARG inhibitor – FORX-428 – for the treatment of cancer. FORX-428 is a highly potent, selective and orally bioavailable PARG inhibitor that showed strong and reversible binding to the catalytic domain of the human PARG enzyme.
Based on positive phase III study results, Metis Techbio is planning to file an NDA for its AI-derived orally disintegrating tablet drug candidate for pseudobulbar affect, MTS-004, in China next year.
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate payloads and targets.
Amphista Therapeutics Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an F-Box only protein 22 (FBXO22)-binding moiety coupled to a transcriptional enhancer factor TEF (TEAD)-targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS
